Liming Bao
YOU?
Author Swipe
View article: Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG).
Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG). Open
Introduction Bruton's tyrosine kinase inhibitors (BTKi), anti-CD20 antibodies, and B cell lymphoma 2 inhibitors (BCL-2i) are essential therapeutic drug classes in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CL…
View article: Co-mapping clonal and transcriptional heterogeneity in somatic evolution via got-multi.
Co-mapping clonal and transcriptional heterogeneity in somatic evolution via got-multi. Open
Somatic evolution drives cancer progression and therapy resistance. Underlying phenotypic progressions is the development of marked clonal heterogeneity in most cancers. However, deciphering the downstream molecular effects of clonal heter…
View article: Bone Metabolic Changes and Osteoporosis During Pregnancy and Lactation: A View from Dental Medicine
Bone Metabolic Changes and Osteoporosis During Pregnancy and Lactation: A View from Dental Medicine Open
Pregnancy- and lactation-associated osteoporosis (PLO) is receiving increasing attention. During pregnancy and lactation, bone metabolism is dramatically changed to supply minerals to the fetus and infant, which is a major cause of PLO. We…
View article: Co-mapping clonal and transcriptional heterogeneity in somatic evolution via GoT-Multi
Co-mapping clonal and transcriptional heterogeneity in somatic evolution via GoT-Multi Open
Somatic evolution leads to clonal heterogeneity, which fuels cancer progression and therapy resistance. To decipher the consequences of clonal heterogeneity, we require a method that deconvolutes complex clonal architectures and their down…
View article: Identification and validation of NEIL2 as a prognostic biomarker and potential therapeutic target in cervical cancer
Identification and validation of NEIL2 as a prognostic biomarker and potential therapeutic target in cervical cancer Open
The expression level of NEIL2 has a strong correlation with CC and affects its prognosis, which is expected to become a new prognostic biomarker in CC, providing an important reference for the diagnosis, mechanism research and treatment of…
View article: Mitochondrial GRIM19 Loss Induces Liver Fibrosis through NLRP3/IL33 Activation via Reactive Oxygen Species/NF-кB Signaling
Mitochondrial GRIM19 Loss Induces Liver Fibrosis through NLRP3/IL33 Activation via Reactive Oxygen Species/NF-кB Signaling Open
The mitochondrial GRIM19 loss facilitates liver fibrosis through NLRP3/IL33 activation via ROS/NF-кB signaling, providing potential therapeutic approaches for earlier HF prevention.
View article: High Grade B-Cell Lymphoma with 11q Aberration Is Not a Rare Event in HIV-Associated Lymphoma
High Grade B-Cell Lymphoma with 11q Aberration Is Not a Rare Event in HIV-Associated Lymphoma Open
High grade B-cell lymphoma with 11q aberration/diffuse large cell lymphoma with 11q aberration (HGBL-11q; previously classified as Burkitt-like lymphoma with 11q aberration, a provisional category in WHO 4-revised) is a relatively new enti…
View article: An Observational Prospective Cohort Study of Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection of an Aerosolized, Inhaled Adenovirus Type 5–Vectored Coronavirus Disease 2019 Vaccine Given as a Second Booster Dose in Guangzhou City, China
An Observational Prospective Cohort Study of Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection of an Aerosolized, Inhaled Adenovirus Type 5–Vectored Coronavirus Disease 2019 Vaccine Given as a Second Booster Dose in Guangzhou City, China Open
Using a prospective, observational cohort study during the post–“dynamic COVID-zero” wave in China, we estimated short-term relative effectiveness against Omicron BA.5 infection of inhaled aerosolized adenovirus type 5–vectored ancestral s…
View article: Two p53s in a Pod: Co‐occurring plasma cell myeloma and therapy‐related myeloid neoplasm following lenalidomide therapy
Two p53s in a Pod: Co‐occurring plasma cell myeloma and therapy‐related myeloid neoplasm following lenalidomide therapy Open
Jorge Monge receives consulting fees from Bristol Myers Squibb. Meri Razavi, Liming Bao, and Sanjay S. Patel have no conflicts of interest to disclose.
View article: Real-World Effectiveness of Primary Series and Booster Doses of Inactivated Coronavirus Disease 2019 Vaccine Against Omicron BA.2 Variant Infection in China: A Retrospective Cohort Study
Real-World Effectiveness of Primary Series and Booster Doses of Inactivated Coronavirus Disease 2019 Vaccine Against Omicron BA.2 Variant Infection in China: A Retrospective Cohort Study Open
Background China has been using inactivated coronavirus disease 2019 (COVID-19) vaccines as primary series and booster doses to protect the population from severe to fatal COVID-19. We evaluated primary and booster vaccine effectiveness (V…
View article: Supplementary figure 2 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Supplementary figure 2 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma Open
miR-221 enhances the expression of MYCN mRNA in NB cells.
View article: Supplementary figure 3 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Supplementary figure 3 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma Open
miR-221 expression in NB cells and tumor xenografts.
View article: Supplementary figure 2 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Supplementary figure 2 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma Open
miR-221 enhances the expression of MYCN mRNA in NB cells.
View article: Supplementary table 1 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Supplementary table 1 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma Open
Patient characteristics
View article: Contribution Form from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Contribution Form from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma Open
Conflict of Interest Form
View article: Supplementary table 1 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Supplementary table 1 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma Open
Patient characteristics
View article: Conflict Disclosure from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Conflict Disclosure from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma Open
Conflict of Interest Form
View article: Supplementary text from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Supplementary text from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma Open
Supplementary data
View article: Data from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Data from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma Open
Purpose:MYCN is one of the most well-characterized genetic markers of neuroblastoma. However, the mechanisms as to how MYCN mediate neuroblastoma tumorigenesis are not fully clear. Increasing evidence has confirmed that the dysregulation o…
View article: Supplementary figure 4 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Supplementary figure 4 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma Open
Effects of miR-221 on the mRNA levels of cell cycle genes, including p21, p27, p57, C-MYC, and CCND1 in NB cells.
View article: Supplementary table 2 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Supplementary table 2 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma Open
The correlation of miR-221 expression with clinicopathologic features in NB patients
View article: Supplementary figure 1 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Supplementary figure 1 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma Open
Assessment of MYCN mRNA expression in human NB cells by qRT-PCR.
View article: Supplementary figure 1 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Supplementary figure 1 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma Open
Assessment of MYCN mRNA expression in human NB cells by qRT-PCR.
View article: Supplementary table 3 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Supplementary table 3 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma Open
The predicted targets for hsa-miR-221
View article: Supplementary figure 3 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Supplementary figure 3 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma Open
miR-221 expression in NB cells and tumor xenografts.
View article: Supplementary table 2 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Supplementary table 2 from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma Open
The correlation of miR-221 expression with clinicopathologic features in NB patients
View article: Copyright Transfer from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma
Copyright Transfer from microRNA-221 Enhances MYCN via Targeting Nemo-like Kinase and Functions as an Oncogene Related to Poor Prognosis in Neuroblastoma Open
Conflict of Interest Form